China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026)
China Pharma Holdings (CPHI) reported Change in Account Payables of -$67771.0 for Q1 2026, down 120.99% on a YoY basis from $322935.0 in Q1 2025, and down 123.19% quarter-over-quarter from $292259.0 in Q4 2025.
China Pharma Holdings (CPHI) Change in Account Payables (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Change in Account Payables for 17 years, with the latest figure at -$67771.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 120.99% year-over-year to -$67771.0; the trailing twelve-month figure through Mar 2026 stood at $259603.0 (up 374.97% YoY), and the FY2025 full-year result was $650309.0, up 188.61% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$67771.0, down from $292259.0 in the prior quarter.
- The five-year high for Change in Account Payables was $442807.0 in Q3 2023, with the low at -$505339.0 in Q2 2024.
- Historically, Change in Account Payables has averaged -$1592.2 across 5 years, with a median of $54437.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 3045.77% — and 2024, when it slumped 414.87%.
- China Pharma Holdings' Change in Account Payables stood at $238485.0 in 2022, then slumped by 54.75% to $107922.0 in 2023, then slumped by 244.32% to -$155753.0 in 2024, then jumped by 287.64% to $292259.0 in 2025, then plunged by 123.19% to -$67771.0 in 2026.
- The last three Change in Account Payables figures came in at -$67771.0 (Q1 2026), $292259.0 (Q4 2025), and $54437.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 62.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 167.64 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 190,000.00 |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 | -67,771.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67,771.00 |
| Mar 31, 2026 | -67,771.00 |
| Dec 31, 2025 | 292,259.00 |
| Dec 31, 2025 | 292,259.00 |
| Sep 30, 2025 | 54,437.00 |
| Sep 30, 2025 | 54,437.00 |
| Jun 30, 2025 | -19,322.00 |
| Jun 30, 2025 | -19,322.00 |
| Mar 31, 2025 | 322,935.00 |
| Mar 31, 2025 | 322,935.00 |
| Dec 31, 2024 | -155,753.00 |
| Dec 31, 2024 | -155,753.00 |
| Sep 30, 2024 | 243,744.00 |
| Sep 30, 2024 | 243,744.00 |
| Jun 30, 2024 | -505,339.00 |
| Jun 30, 2024 | -505,339.00 |
| Mar 31, 2024 | -316,568.00 |
| Mar 31, 2024 | -316,568.00 |
| Dec 31, 2023 | 107,922.00 |
| Dec 31, 2023 | 107,922.00 |